O10 A national retrospective cohort study of the incidence and trends of 3061 cases of cutaneous T-cell lymphoma in England between 2013 and 2020

Charlotte Sheern,Nick J Levell,Polly Jeffrey,Khaylen Mistry,Matthew J Scorer,Zoe C Venables

DOI: https://doi.org/10.1093/bjd/ljae090.010

IF: 11.113

2024-06-28

British Journal of Dermatology

Abstract:Abstract There are limited epidemiological data available for cutaneous T-cell lymphoma (CTCL). This retrospective, national cohort study reported CTCL incidence from 2013 to 2020, including the early impact of the COVID-19 pandemic. National data were extracted from the ‘Get Data Out’ National Disease Registration Service, haematological malignancies dataset. Crude incidence rates (CIRs) were reported per 100 000 person-years (PY) from 2013 to 2020. Joinpoint regression was used to assess trends and annual percentage change from 2013 to 2019. Incidence rate ratios with Poisson regression were used to assess the early impact of COVID-19 on CIR in 2020 vs. 2019. In total, 3061 new cases of CTCL were diagnosed in England between 2013 and 2020 (mean 383 new diagnoses per year). The CIR was 0.69 PY over the whole period, 0.75 PY [95% confidence interval (CI) 0.68–0.83] in 2013, and 0.60 PY (95% CI 0.54–0.67) in 2020. Over the 8 years analysed, 38% of patients (1153 of 3061) were female and 62% (1908 of 3061) were male (ratio 1 : 1.7). Overall, 61% of patients (1858 of 3061) were aged < 70 years and 39% (1203 of 3061) were aged ≥ 70 years. The annual percentage change from 2013 to 2019 was −1.21% (95% CI −3.52 to 1.15) overall, −2.36% (95% CI −9.65 to 5.30) in those aged < 70 years, and −0.96% (95% CI −4.03 to 2.40) in those aged ≥ 70 years. During the early COVID-19 pandemic, the CIR fell significantly, by 15%, from 0.71 PY (95% CI 0.64–0.78) in 2019 to 0.60 PY (95% CI 0.54–0.67) in 2020 (P = 0.02, incidence rate ratio = 0.85). This is the first and largest national dataset to report the incidence of CTCL in England. The number of diagnoses per year reduced over the period, with a greater reduction seen in patients aged < 70 years; however, these trends were not significant. A fall in incidence was observed during the early COVID-19 pandemic. The time from first presentation to diagnosis of CTCL is approximately 6 years. The data were limited by the complex variety of clinical, histological and molecular features of CTCL, which make diagnosis challenging. Higher incidences have been described internationally, with a CIR of 0.86 PY reported in the USA, and 0.96 PY in France. Cases that did not have a histological diagnosis or dataset completed by a multidisciplinary team meeting may have been missed. Limitations of the study include a lack of data on ethnic groups and CTCL subtypes. These data are essential in expanding our knowledge of the changes in national CTCL epidemiology, and supporting ongoing research.

dermatology